Nonantibiotic properties of tetracyclines: Structural basis for inhibition of secretory phospholipase A2

Journal of Molecular Biology

Volumn 398, Issue 1, 2010, Pages 83-96

  Dalm, Daniela ^a   Palm, Gottfried J ^a   Aleksandrov, Alexey ^b   Simonson, Thomas ^b   Hinrichs, Winfried ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b LABORATOIRE DE BIOCHIMIE   (France)

Author keywords

Anti inflammatory; Minocycline; Nonantibiotic; Phospholipase; X ray crystallography

Indexed keywords

MINOCYCLINE; SECRETORY PHOSPHOLIPASE A2;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM BINDING; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; PRIORITY JOURNAL; SNAKE; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

NAJA NAJA NAJA;

EID: 77950861082     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.02.049     Document Type: Article

References (53)

1. Golub L.M., Ramamurthy N.S., McNamara T.F., Greenwald R.A., Rifkin B.R. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit. Rev. Oral Biol. Med. 1991, 2:297-321.
2. Eklund K.K., Sandler C. Antibiotic or anti-inflammatory agent? The double-edged sword of tetracyclines. Anti-Inflamm. Anti-Allerg. Agents Med. Chem. 2007, 6:253-263.
3. 2 by minocycline and doxycycline. Biochem. Pharmacol. 1992, 44:1165-1170.
4. Hamdan II, Afifi F., Taha M.O. In vitro alpha amylase inhibitory effect of some clinically-used drugs. Pharmazie 2004, 59:799-801.
5. 2. J. Biol. Chem. 1994, 269:13057-13060.
6. Dennis E.A. The Enzymes 1983, vol. 16:307-353. Academic Press, New York, NY. third edit. P. Boyer (Ed.).
7. 2. Am. J. Pathol. 1989, 134:807-811.
8. 2 in acute pancreatitis. Z. Med. Lab. Diagn. 1989, 30:299-303.
9. 2. J. Biochem. 1989, 106:518-527.
10. 2. Toxicon 1998, 36:1623-1633.
11. 2. Biochemistry 1993, 32:6485-6492.
12. 2 with a transition-state analogue. Acta Crystallogr. Sect. D 1998, 54:334-341.
13. 2 from Daboia russelli pulchella with an endogenic indole derivative, 2-carbamoylmethyl-5-propyl-octahydro-indol-7-yl-acetic acid at 1.8 Å resolution. Biochim. Biophys. Acta 2005, 1752:177-185.
14. 2 with a Group II-specific peptide Leu-Ala-Ile-Tyr-Ser (LAIYS) at 2.6 Å resolution. J. Drug Targeting 2005, 13:367-374.
15. 2 with two natural anti-inflammatory agents, anisic acid, and atropine reveal a similar mode of binding. Proteins 2006, 64:89-100.
16. 2 and diclofenac at 2.7 Å resolution. Acta Crystallogr. Sect. D 2006, 62:410-416.
17. 2. J. Rheumatol. 1998, 25:1807-1812.
18. O'Dell J.R., Haire C.E., Palmer W., Drymalski W., Wees S., Blakely K., et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1997, 40:842-848.
19. Tilley B.C., Alarcon G.S., Heyse S.P., Trentham D.E., Neuner R., Kaplan D.A., et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann. Intern. Med. 1995, 122:81-89.
20. 2+ reveal trimeric packing. J. Mol. Biol. 1998, 279:223-232.
21. 2 from Indian cobra reveals a trimeric association. Proc. Natl Acad. Sci. USA 1993, 90:342-346.
22. Kabsch W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. Sect. A 1976, 32:922-923.
23. Aleksandrov A., Proft J., Hinrichs W., Simonson T. Protonation patterns in tetracycline:tet repressor recognition: simulations and experiments. ChemBioChem 2007, 8:675-685.
24. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007, 372:774-797.
25. 2+ complex: a molecular mechanics force field. J. Comput. Chem. 2006, 27:1517-1533.
26. Meyer E.A., Castellano R.K., Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew. Chem. Int. Ed. Engl. 2003, 42:1210-1250.
27. 2. Nature 1981, 289:604-606.
28. Satow Y., Cohen G.H., Padlan E.A., Davies D.R. Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 Å. J. Mol. Biol. 1986, 190:593-604.
29. 2-a structural review. Toxicon 1996, 34:827-841.
30. Szabo A., Stolz L., Granzow R. Surface plasmon resonance and its use in biomolecular interaction analysis (BIA). Curr. Opin. Struct. Biol. 1995, 5:699-705.
31. Brodersen D.E., Clemons W.M., Carter A.P., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 2000, 103:1143-1154.
32. Pioletti M., Schlünzen F., Harms J., Zarivach R., Gluhmann M., Avila H., et al. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 2001, 20:1829-1839.
33. 2+ ion initiates helix unwinding in Tet repressor induction. Biochemistry 1999, 38:191-198.
34. Heffron S.E., Mui S., Aorora A., Abel K., Bergmann E., Jurnak F. Molecular complementarity between tetracycline and the GTPase active site of elongation factor Tu. Acta Crystallogr. Sect. D 2006, 62:1392-1400.
35. Palm G.J., Lederer T., Orth P., Saenger W., Takahashi M., Hillen W., Hinrichs W. Specific binding of divalent metal ions to tetracycline and to the Tet repressor/tetracycline complex. J. Biol. Inorg. Chem. 2008, 13:1097-1110.
36. + antiporter of Escherichia coli encoded by a transposon, Tn10. The role of the conserved dipeptide, Ser65-Asp66, in tetracycline transport. J. Biol. Chem. 1990, 265:15525-15530.
37. Hinrichs W., Kisker C., Düvel M., Müller A., Tovar K., Hillen W., Saenger W. Structure of the Tet repressor-tetracycline complex and regulation of antibiotic resistance. Science 1994, 264:418-420.
38. 2+ reveals mechanism of antibiotic resistance. J. Mol. Biol. 1995, 247:260-280.
39. 2 from Bungarus caeruleus at 2.1 Å resolution. J. Struct. Biol. 2005, 149:264-272.
40. 2. J. Mol. Biol. 2007, 369:439-450.
41. 2 from the venom of Naja kaouthia. Toxicon 2002, 40:917-922.
42. 2 from common krait (Bungarus caeruleus) at 2.5 Å resolution. Acta Crystallogr. Sect. F 2005, 61:8-13.
43. 2. Biochemistry 1985, 24:6152-6158.
44. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA, USA.
45. 2 from cobra venom (Naja naja naja). Methods Enzymol. 1981, 71:703-710.
46. Pflugrath J.W. The finer things in X-ray diffraction data collection. Acta Crystallogr. Sect. D 1999, 55:1718-1725.
47. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D 1994, 50:760-763.
48. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
49. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 2004, 60:2126-2132.
50. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D 1997, 53:240-255.
51. Winn M.D., Isupov M.N., Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. Sect. D 2001, 57:122-133.
52. Lovell S.C., Davis I.W., Adrendall W.B., de Bakker P.I.W., Word J.M., Prisant M.G., et al. Structure validation by C alpha geometry: phi,psi and C beta deviation. Proteins 2003, 50:437-450.
53. Nieba L., Krebber A., Pluckthun A. Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal. Biochem. 1996, 234:155-165.